BIOTECH (90) – Iovance Biotherapeutics: FDA Accelerated Approval of lifileucel (Amtagvi), the first Tumour-Infiltrating Lymphocyte (TIL) Cancer Therapy February 19, 2024
BIOTECH (89) Cymabay Therapeutics: Seladelpar, an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist February 18, 2024February 19, 2024
BIOTECH (87) – Gilead’s Magrolimab (Hu5F9-G4) CD47-SIRPα blocker with Azacitidine for AML Phase 3 ENHANCE Study Terminated & Solid Tumor Partial Clinical Hold February 18, 2024
BIOTECH (86) – Kyverna Therapeutics: Autoimmune Disease CAR-T Therapy with Ingenui-T Manufacturing February 17, 2024February 17, 2024